Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 72-79

  Hattori, Junko ^a   Shiino, Teiichiro ^b   Gatanaga, Hiroyuki ^c   Yoshida, Shigeru ^d   Watanabe, Dai ^e   Minami, Rumi ^e   Sadamasu, Kenji ^f   Kondo, Makiko ^g   Mori, Haruyo ^h   Ueda, Mikio ⁱ   Tateyama, Masao ^j   Ueda, Atsuhisa ^k   Kato, Shingo ^l   Ito, Toshihiro ^e   Oie, Masayasu ^m   Takata, Noboru ⁿ   Hayashida, Tsunefusa ^c   Nagashima, Mami ^f   Matsuda, Masakazu ^o   Ibe, Shiro ^a   Ota, Yasuo ^p   Sasaki, Satoru ^e   Ishigatsubo, Yoshiaki ^k   Tanabe, Yoshinari ^m   Koga, Ichiro ^p   Kojima, Yoko ^h   Yamamoto, Masahiro ^e   Fujita, Jiro ^j   Yokomaku, Yoshiyuki ^a   Koike, Takao ^q   Shirasaka, Takuma ^e   Oka, Shinichi ^c   Sugiura, Wataru ^a,b,r   more..

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

^g KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^h OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

ⁱ ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^j UNIVERSITY OF THE RYUKYUS   (Japan)

^k YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

ⁿ HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^o LSI MEDIENCE CORPORATION   (Japan)

^p TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^r NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

BED assay; Drug resistant HIV 1; Newly diagnosed HIV AIDS patients; Prevalence; Treatment na ve

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; DEMOGRAPHY; DISEASE TRANSMISSION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; JAPAN; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; REVERTANT; TREND STUDY; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DATA COLLECTION; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; JAPAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956924027     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.07.008     Document Type: Article

References (38)

1. Apisarnthanarak A., Jirayasethpong T., Sa-nguansilp C., Thongprapai H., Kittihanukul C., Kamudamas A., Tungsathapornpong A., Mundy L.M. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med. 2008, 9:322-325.
2. Audelin A.M., Lohse N., Obel N., Gerstoft J., Jørgensen L.B. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir. Ther. 2009, 14:995-1000.
3. Bártolo I., Rocha C., Bartolomeu J., Gama A., Fonseca M., Mendes A., Cristina F., Thamm S., Epalanga M., Silva P.C., Taveira N. Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance. Antimicrob. Agents Chemother. 2009, 53:3156-3158.
4. Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M., Heneine W., Kantor R., Jordan M.R., Schapiro J.M., Vandamme A.M., Sandstrom P., Boucher C.A., van de Vijver D., Rhee S.Y., Liu T.F., Pillay D., Shafer R.W. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4:e4724.
5. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., Tsay J., Ip J., Farthing C., Limoli K., Parkin N., Markowitz M. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
6. Chaix M.L., Descamps D., Wirden M., Bocket L., Delaugerre C., Tamalet C., Schneider V., Izopet J., Masquelier B., Rouzioux C., Meyer L., Costagliola D. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009, 23:717-724.
7. Chang S.Y., Chen M.Y., Lee C.N., Sun H.Y., Ko W., Chang S.F., Chang K.L., Hsieh S.M., Sheng W.H., Liu W.C., Wu C.H., Kao C.L., Hung C.C., Chang S.C. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J. Antimicrob. Chemother. 2008, 61:689-693.
8. de Mendoza C., Rodriguez C., Eiros J.M., Colomina J., Garcia F., Leiva P., Torre-Cisneros J., Aguero J., Pedreira J., Viciana I., Corral A., del Romero J., Ortiz de Lejarazu R., Soriano V. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin. Infect. Dis. 2005, 41:227-232.
9. DHHS Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2009.
10. Dunn D., Geretti A.M., Green H., Fearnhill E., Pozniak A., Churchill D., Pillay D., Sabin C., Phillips A. Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir. Ther. 2008, 13:771-777.
11. Eshleman S.H., Husnik M., Hudelson S., Donnell D., Huang Y., Huang W., Hart S., Jackson B., Coates T., Chesney M., Koblin B. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 2007, 21:1165-1174.
12. Fujisaki S., Fujisaki S., Ibe S., Asagi T., Itoh T., Yoshida S., Koike T., Oie M., Konda M., Sadamasu K., Nagashima M., Gatanaga H., Matsuda M., Ueda M., Masakane A., Hata M., Mizogami Y., Mori H., Minami R., Okada K., Watanabe K., Shirasaka T., Oka S., Sugiura W., Kaneda T. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Jpn. J. Infect. Dis. 2007, 60:113-117.
13. Gallego O., Ruiz L., Vallejo A., Ferrer E., Rubio A., Clotet B., Leal M., Soriano V. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 2001, 15:1894-1896.
14. Gatanaga H., Ibe S., Matsuda M., Yoshida S., Asagi T., Kondo M., Sadamasu K., Tsukada H., Masakane A., Mori H., Takata N., Minami R., Tateyama M., Koike T., Itoh T., Imai M., Nagashima M., Gejyo F., Ueda M., Hamaguchi M., Kojima Y., Shirasaka T., Kimura A., Yamamoto M., Fujita J., Oka S., Sugiura W. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res. 2007, 75:75-82.
15. Gómez-Cano M., Rubio A., Puig T., Pérez-Olmeda M., Ruiz L., Soriano V., Pineda J.A., Zamora L., Xaus N., Clotet B., Leal M. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998, 12:1015-1020.
16. Granich R.M., Gilks C.F., Dye C., De Cock K.M., Williams B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
17. Halvas E.K., Wiegand A., Boltz V.F., Kearney M., Nissley D., Wantman M., Hammer S.M., Palmer S., Vaida F., Coffin J.M., Mellors J.W. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J. Infect. Dis. 2010, 201:672-680.
18. Hirsch M.S., Brun-Vézinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
19. Hirsch M.S., Günthard H.F., Schapiro J.M., Brun-Vézinet F., Clotet B., Hammer S.M., Johnson V.A., Kuritzkes D.R., Mellors J.W., Pillay D., Yeni P.G., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 2008, 47:266-285.
20. Ishizaki A., Cuong N.H., Thuc P.V., Trung N.V., Saijoh K., Kageyama S., Ishigaki K., Tanuma J., Oka S., Ichimura H. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res. Hum. Retroviruses 2009, 25:175-182.
21. Lall M., Gupta R.M., Sen S., Kapila K., Tripathy S.P., Paranjape R.S. Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res. Hum. Retroviruses 2008, 24:987-990.
22. Lima V.D., Gill V.S., Yip B., Hogg R.S., Montaner J.S., Harrigan P.R. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J. Infect. Dis. 2008, 198:51-58.
23. Los-Alamos HIV Databases 2010, http://www.hiv.lanl.gov/content/index.
24. Maia Teixeira S.L., Bastos F.I., Hacker M.A., Guimarães M.L., Morgado M.G. Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro. J. Med. Virol. 2006, 78:764-769.
25. Mintsa-Ndong A., Caron M., Plantier J.C., Makuwa M., Le Hello S., Courgnaud V., Roques P., Kazanji M. High HIV Type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa. AIDS Res. Hum. Retroviruses 2009, 25:411-418.
26. Ndembi N., Lyagoba F., Nanteza B., Kushemererwa G., Serwanga J., Katongole-Mbidde E., Grosskurth H., Kaleebu P. Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe Uganda. AIDS Res. Hum. Retroviruses 2008, 24:889-895.
27. Nouhin J., Ngin S., Martin P.R., Marcy O., Kruy L., Ariey F., Peeters M., Chaix M.L., Ayouba A., Nerrienet E. Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia. AIDS Res. Hum. Retroviruses 2009, 25:543-545.
28. Ockenga J., Tillmann H.L., Trautwein C., Stoll M., Manns M.P., Schmidt R.E. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J. Hepatol. 1997, 27:18-24.
29. Palma A.C., Araújo F., Duque V., Borges F., Paixão M.T., Camacho R. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect. Genet. Evol. 2007, 7:391-398.
30. Pillay V., Ledwaba J., Hunt G., Rakgotho M., Singh B., Makubalo L., Bennett D.E., Puren A., Morris L. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir. Ther. 2008, 13(Suppl. (2)):101-107.
31. Piroth L., Grappin M., Cuzin L., Mouton Y., Bouchard O., Raffi F., Rey D., Peyramond D., Gourdon F., Drobacheff C., Lombart M.L., Lucht F., Besnier J.M., Bernard L., Chavanet P., Portier H. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J. Viral Hepat. 2000, 7:302-308.
32. Sagir A., Oette M., Kaiser R., Däumer M., Fätkenheuer G., Rockstroh J.K., Knechten H., Schmutz G., Hower M., Emmelkamp J., Pfister H., Haussinger D. Trends of prevalence of primary HIV drug resistance in Germany. J. Antimicrob. Chemother. 2007, 60:843-848.
33. Tambussi G., Boeri E., Carrera P., Gianotti N., Lazzarin A. Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997. J. Biol. Regul. Homeost. Agents 1998, 12:32-34.
34. Varghese V., Shahriar R., Rhee S.Y., Liu T., Simen B.B., Egholm M., Hanczaruk B., Blake L.A., Gharizadeh B., Babrzadeh F., Bachmann M.H., Fessel W.J., Shafer R.W. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 2009, 52:309-315.
35. Vercauteren J., Derdelinckx I., Sasse A., Bogaert M., Ceunen H., De Roo A., De Wit S., Deforche K., Echahidi F., Fransen K., Goffard J.C., Goubau P., Goudeseune E., Yombi J.C., Lacor P., Liesnard C., Moutschen M., Pierard D., Rens R., Schrooten Y., Vaira D., Van den Heuvel A., Van Der Gucht B., Van Ranst M., Van Wijngaerden E., Vandercam B., Vekemans M., Verhofstede C., Clumeck N., Vandamme A.M., Van Laethem K. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res. Hum. Retroviruses 2008, 24:355-362.
36. Vercauteren J., Wensing A.M., van de Vijver D.A., Albert J., Balotta C., Hamouda O., Kücherer C., Struck D., Schmit J.C., Asjö B., Bruckova M., Camacho R.J., Clotet B., Coughlan S., Grossman Z., Horban A., Korn K., Kostrikis L., Nielsen C., Paraskevis D., Poljak M., Puchhammer-Stockl E., Riva C., Ruiz L., Salminen M., Schuurman R., Sonnerborg A., Stanekova D., Stanojevic M., Vandamme A.M., Boucher C.A. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 2009, 200:1503-1508.
37. Wheeler W.H., Ziebell R.A., Zabina H., Pieniazek D., Prejean J., Bodnar U.R., Mahle K.C., Heneine W., Johnson J.A., Hall H.I. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses U.S.-2006. AIDS 2010, 24:1203-1212.
38. Zajdenverg R., Badal-Faesen S., Andrade-Villanueva J. Lopinavir/ritonavir (LPV/r) tablets administered once- (QD) or twice-daily (BID) with NRTIs in antiretroviral-experienced HIV-1 infected subjects: results of a 48-week randomized trial (study M06-802). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa 2009.